Science
Scientists and research leaders expanding knowledge across Asia and its global diaspora.
Nithin Kamath Is Turning Zerodha’s Profits Into Patient Capital. Rainmatter Needs Portfolio Accountability
Rainmatter has expanded from fintech partnerships into a broad portfolio and a foundation supporting climate and livelihoods. Nithin Kamath must show how patient capital learns, recycles returns and remains accountable when it avoids board seats and fixed exits.
Huda Kattan Bought Back Huda Beauty. Founder Control Must Now Fund Its Own Growth
Huda Kattan has placed social-led product discovery, colour cosmetics, direct consumer relationships and selective distribution through retailers such as Sephora at the centre of the strategy. The next phase will test capital discipline, execution and durability across Asia.
Feng Zhang Won $34.5 Million for Paediatric Epilepsy Editing. A Shared Platform Must Defeat Rare-Disease Economics
Feng Zhang’s ARPA-H-backed PERC consortium targets two severe childhood epilepsies first. Its real value will be whether one platform can lower the cost of treating many ultra-rare diseases.
Demis Hassabis Moved DeepMind Deeper Into the Laboratory. Scientific AI Needs a Verification Business Model
Demis Hassabis is building a wider scientific-AI stack around AlphaGenome and Co-Scientist. The opportunity is large, but laboratories need reproducible gains rather than fluent novelty.
Chuan He Connected Diet, RNA Marks and Early Immunity. Product Builders Must Separate Signal From Platform
Chuan He’s latest research brings RNA regulation into early-life immunity, learning and development. The opportunity is broad, but commercial claims must stay behind causal evidence.
Anima Anandkumar Put Neural Operators on Firmer Ground. Scientific AI Must Earn Its Compute
Anima Anandkumar’s neural-operator research targets reusable scientific models rather than one-off predictions. Adoption will depend on verification, compute economics and domain trust.
Reshma Kewalramani Has Opened Vertex's Fourth Franchise. Kidney Medicine Must Now Match the Cystic Fibrosis Standard
Vertex is building beyond cystic fibrosis, with kidney medicine its newest large opportunity. Reshma Kewalramani must turn povetacicept into a durable franchise.
Shimon Sakaguchi Extended Treg Science Into Cancer and Heart Failure. Translation Must Now Prove Its Range
Shimon Sakaguchi’s 2026 research links Treg biology to checkpoint response and heart-failure fibrosis. Platform value will depend on reproducibility, manufacturing and patient selection.
